Aleafia Health Inc ALEAF

Aleafia Health Inc. is a federally licensed Canadian cannabis company offering cannabis products in Canadian adult-use and medical markets and in select international markets. The Company is engaged in the production, sale, and distribution of cannabis. It operates a virtual medical cannabis clinic staffed by physicians and nurse practitioners which provide health and wellness services across Canada. The Company operates two licensed cannabis production facilities and operates a strategically located distribution center all in the province of Ontario, including the largest, outdoor cannabis cultivation facility in Canada. The Company produces a diverse portfolio of cannabis and cannabis derivative products including dried flower, pre-roll, milled, vapes, oils, capsules, edibles, sublingual strips and topicals. It markets and sells cannabis products through regulated intermediaries into selected international markets, tactically sells cannabis products into Canadian wholesale markets.

GREY:ALEAF - Post by User

Aleafia Health Inc > LOL! No kidding Barclays

<< Previous

Bullboard Posts

Next >>

Comment by Toweringmarson Nov 18, 2021 1:04pm

98 Views

Post# 34141584

RE:RE:LOL! No kidding Barclays

Siiiiiiiiigh
Get the last word in keezie.
You're truly a man of the people.

KeyserShoze wrote: Big lol. Aleafia ran to $1.28 in February on US legalization hype. They wouldn't even have been able to raise that $22 million with out that hype. But no kidding Barclay's.

sthinei wrote: They will benefit from Germany though.

Canadian firms unlikely to benefit from U.S. cannabis growth - Barclays

Nov. 18, 2021 9:32 AM ETTilray, Inc. (TLRY), CRON,CGCMMNFFBy: Dulan Lokuwithana, SA News Editor19 Comments

Kazyaka/iStock via Getty Images

Barclays has started the coverage on several Canadian Licensed Producers with less than favorable recommendations arguing that they are unlikely to gain a sizable advantage from potential federal legalization of cannabis in the U.S.

The analysts have issued Underweight ratings on Tilray (NASDAQ:TLRY) and Cronos Group (NASDAQ:CRON) which were trading ~3.3% and ~1.1% lower in the pre-market, respectively. The price target for Tilray (TLRY) at $10 per share indicates a downside of ~19% while that for Cronos (CRON) at $5.5 per share implies a downside of ~1% to the last close.

Meanwhile, the firm has rated Canopy Growth (NASDAQ:CGC) with an Equal-weight recommendation with the price target of $14 per share implying a premium of ~3% to the last close. Canopy (CGC) was trading flat in the pre-market.

The analysts point out that a majority of the enterprise value of the above stocks have been attributed to their potential in the U.S. market while the firms cannot directly invest in the U.S market.

They observe that the companies have entered into deals with the U.S. MSOs seeking minority stakes in the event of a federal legalization of cannabis in the U.S.

“We think the benefit of these deals accrues to the shareholders of MSOs rather than those of the Canadian companies,” the team of analysts argued.

In a transaction with MedMen Enterprises (OTCQB:MMNFF), Tilray (TLRY) took a major bet on the U.S. cannabis market a few months ago.